Provectus Biopharmaceuticals, INC 10-Q quarterly reports

Provectus Biopharmaceuticals, Inc. reported its Q2 2026 financial results, highlighting reduced operating expenses but also substantial doubt regarding its ability to continue as a going concern.

Provectus Biopharmaceuticals reported a wider net loss for Q1 2026 compared to the prior year, primarily due to the absence of grant revenue and a decrease in operating expenses.

Provectus Biopharmaceuticals reported a significantly wider net loss in Q3 2025, driven by increased operating expenses and a complete cessation of grant revenue, raising substantial doubt about its ability to continue as a going concern.

Provectus Biopharmaceuticals, Inc. reported a significant increase in net loss for Q2 2025, raising substantial doubt about its ability to continue as a going concern.

Provectus Biopharmaceuticals reports increased operating expenses and net losses for Q1 2025, raising substantial doubt about its ability to continue as a going concern.

Provectus Biopharmaceuticals reports a net loss of $1.01 million for Q3 2024, alongside ongoing efforts to secure additional funding and advance its drug development programs.

Provectus Biopharmaceuticals reports a net loss of $1.35 million for the first half of 2024, while continuing to advance its clinical and non-clinical programs.

Provectus Biopharmaceuticals reported a net loss of $504,042 for the first quarter of 2024, alongside ongoing efforts to develop its drug candidates and secure additional funding.